People with type-2 diabetes who take metformin may have an altered ability to metabolize the anti-diabetes drug if they also have non-alcoholic steatohepatitis (NASH). Publishing their findings in the journal Diabetes, researchers conducted research in mice to determine how NASH affects the body’s ability to metabolize metformin.

Their research suggests that humans with NASH likely retain metformin for longer and at higher levels than the normal.  This will likely result in toxic effects to the body.

This research may lead to new protocols that shift the metformin dose based on an individual’s capacity to metabolize the drug.

To read the study abstract, click here.

To read a press release about the study, click here.